Stockwatch: Earnings Move From Mediocre to Worse
Executive Summary
There is now no sugar-coating of the first-quarter 2016 earnings season for life sciences companies. By the end of the previous week a few companies had reported results that didn't disappoint but also didn't blow off any socks. By contrast, the second full week of earnings reports majored in significant disappointment.
You may also be interested in...
Stockwatch: What Links Actimmune And Vertex’s Event Horizon?
Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with.
Q1 Earnings In Brief: Celgene, Alkermes, Novo Nordisk, Acorda, Alexion
First quarter earnings are in full swing. Here is a look at what some companies are saying to analysts during their quarterly calls. Celgene talks up Revlimid; Alkermes bullish on Aristada launch; Victoza market share threatened by Trulicity; Acorda plans for Phase III in post-stroke; Soliris still backbone at Alexion.
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha
Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.